Menten AIMenten AI designs peptide and protein therapeutics using quantum…

Menten AI: Generative AI for Peptide Drug Design

Introduction

Menten AI is revolutionizing peptide drug design with the world's most advanced generative AI platform for peptide therapeutics. By integrating physics-based design with generative machine learning, Menten AI overcomes historical limitations in drug design, creating novel drug-like chemical matter efficiently and with high accuracy.

Key Features

• Physics-Based Design: Leverages first principle physics-based methods for molecular modeling.
• Generative Machine Learning: Creates its own data to guide the design and optimization of novel peptides.
• High Accuracy: Achieves nM potency directly from in silico design with desirable in vitro and in vivo properties.
• Rapid Development: Delivers drug-like hit molecules in a single round of design in just 8 weeks.
• Large Chemical Space: Designs peptide macrocycles in a larger chemical space (10^50 compared to 10^9 for high throughput platforms).

Use Cases

• Undruggable Targets: Enables new types of drugs for currently undruggable targets.
• Peptide Macrocycles: Ideal for undruggable and hard-to-drug targets beyond the reach of small molecules and biologics.
• Anti-Viral Peptides: Validated by creating multiple hit molecules, including an anti-viral peptide for Covid-19.
• Immune-Oncology Applications: Develops bi-functional molecules for the recruitment of cytotoxic immune effectors.

Pricing

Menten AI offers customized pricing based on the specific needs and scale of your drug design projects. Contact us to discuss your requirements and get a tailored quote.

Teams

Backed by top-tier VCs including Uncork Capital, Khosla Ventures, Social Impact Capital, and Y-Combinator, Menten AI's team is dedicated to enabling new types of drugs for undruggable targets using machine learning. Our platform has been validated across the preclinical discovery pipeline, demonstrating efficacy in silico, in vitro, and in vivo. Join us in transforming the future of peptide therapeutics.